Compare Monster Beverage Corp (MNST) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs BIO-TECHNE Corp — how do they compare? Monster Beverage Corp trades at $45.6 (market cap $89.56B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Monster Beverage Corp is far larger — about 8× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| MNST | TECH | |
|---|---|---|
Market Cap | $89.56B | $11.24B |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $72.29 |
52-Week Low | $30.86 | $43.31 |
Enterprise Value | $87.85B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $45.18, down 4.04% in the last 24 hours, with a bearish technical signal. The company reported strong Q2 2026 earnings, beating estimates with $0.60 EPS and record sales of $2.54 billion, driven by international growth. Financials show robust revenue growth from $8.29 billion in 2025 to a projected $9.2 billion in 2026, with net income margins above 23%. A 2-for-1 stock split is scheduled for August 11, 2026.
Outlook remains positive due to consistent earnings beats and global expansion, but high valuation ratios like a P/E of 41.83 pose risks. Analyst consensus is bullish with a $51.14 price target, though competition and economic sensitivity could pressure margins. Investors should weigh growth potential against premium valuation.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
